Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2015-11-09 Interim / Quarterly Rep…
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
FORM 10-Q
Interim / Quarterly Report Q3 2015
2015-11-09 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events. The text specifically mentions that the company issued a press release announcing third quarter financial results and an investor conference call. The document itself does not contain detailed financial statements or comprehensive financial analysis but rather announces the results and the call. The length is only 2706 characters, which is short and consistent with an announcement rather than a full report. Therefore, this is an Earnings Release (ER) type filing, as it announces quarterly financial results highlights and an upcoming call.
2015-11-09 English
SC 13G
Major Shareholding Notification
2015-10-05 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates that the company issued a press release about reaching an agreement with the FDA regarding a Special Protocol Assessment for a Phase 3 clinical trial. The document includes the press release as an exhibit and is signed by the CFO. The length is 2910 characters, which is relatively short and primarily serves as an announcement of an event rather than a detailed financial or management report. There is no substantive financial data, earnings information, or detailed management discussion. The document is not an Annual Report, Interim Report, Earnings Release, or any other detailed report type. It is a regulatory filing announcing a material event, fitting the category of Regulatory Filings (RNS).
2015-09-17 English
QUARTERLY REPORT
Interim / Quarterly Report Q2 2015
2015-08-10 English
Major Shareholding Notification 2015
Major Shareholding Notification
2015-08-10 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.